Unesbulin Plus Dacarbazine for Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
J. Clin. Oncol 2024 Apr 29;[EPub Ahead of Print], BA Van Tine, MA Ingham, S Attia, CF Meyer, JD Baird, E Brooks-Asplund, D D'Silva, R Kong, A Mwatha, K O'Keefe, M Weetall, R Spiegel, GK SchwartzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.